(a) To
assist the local health officer, the laboratory director, or the laboratory
director's designee, of a clinical laboratory, an approved public health laboratory
or a veterinary laboratory in which a laboratory examination of any specimen derived
from the human body (or from an animal, in the case of a disease or condition in
animals made reportable by these regulations) yields microscopic, culture,
immunologic, serologic, molecular, pathologic, or other evidence suggestive of those
diseases listed in subsections (e)(1) and (e)(2) below, shall report such findings
to the health officer of the local health jurisdiction where the patient resides. If
the patient residence is unknown, the laboratory shall notify the health officer of
the jurisdiction in which the health care provider is located. The reporting
specified above shall include any initial findings as well as any subsequent
findings as a result of additional laboratory examination. In addition, the
laboratory director or the laboratory director's designee shall also report negative
laboratory test results or other laboratory findings when requested by the
Department or a local health officer.
(1) For
those diseases listed in subsection (e)(1), the report of such findings shall be
made within one hour after the laboratory notifies the health care provider or other
person authorized to receive the report. If the laboratory that makes the positive
finding received the specimen from another laboratory, the laboratory making the
positive finding shall notify the health officer of the jurisdiction where the
patient resides within one hour from the time the laboratory notifies the referring
laboratory that submitted the specimen. If the patient residence is unknown, the
laboratory shall notify the health officer of the jurisdiction in which the health
care provider is located.
(2) For those
diseases listed in subsection (e)(2), with the exception of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), the report of such findings shall be made
within one working day from the time that the laboratory notifies the health care
provider or other person authorized to receive the report. If the laboratory that
makes the positive finding received the specimen from another laboratory, the
laboratory making the positive finding shall notify the health officer of the
jurisdiction where the patient resides within one working day from the time the
laboratory notifies the referring laboratory that submitted the specimen. If the
patient residence is unknown, the laboratory shall notify the health officer of the
jurisdiction in which the health care provider is located.
(3) For severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the report of such findings shall be made within eight
hours from the time that the laboratory notifies the health care provider or other
person authorized to receive the report. If the laboratory that makes the positive
finding received the specimen from another laboratory, the laboratory making the
positive finding shall notify the health officer of the jurisdiction where the
patient resides within eight hours from the time the laboratory notifies the
referring laboratory that submitted the specimen. If the patient residence is
unknown. the laboratory shall notify the health officer of the jurisdiction in which
the health care provider is located.
(b) To permit local health officer follow-up of
laboratory findings, all specimens submitted for laboratory tests or examinations
related to a disease or condition listed in subsections
2505(e)(1) or
2502(e)(2) shall be
accompanied by a test requisition which includes the name, gender, race, ethnicity,
pregnancy status, address and date-of-birth of the person from whom the specimen was
obtained and the name, address and telephone number of the health care provider or
other authorized person who submitted the specimen. Whenever the specimen, or an
isolate therefrom, is transferred between laboratories, a test requisition with the
above patient and submitter information shall accompany the specimen. The laboratory
that first receives a specimen shall be responsible for obtaining the patient and
submitter information at the time the specimen is received by that
laboratory.
(c) Each notification to the
local health officer shall include the date the specimen was obtained, the patient
identification number, the specimen accession number or other unique specimen
identifier, the specimen site, the diagnosis code, the laboratory findings for the
test performed, the date that the laboratory findings were identified, the name,
gender, race, ethnicity, address, telephone number (if known), pregnancy status, and
date of birth of the person from whom the specimen was obtained, and the name,
address, and telephone number of the health care provider for whom such examination
or test was performed. Laboratories shall report the elements specified above in a
format specified by the Department.
(d)
The notification shall be submitted as specified in subsections (e)(1) and (e)(2) of
this Section to the local health officer in the jurisdiction where the patient
resides. When the specimen is from an out-of-state submitter, the state
epidemiologist of the submitter shall be provided the same positive findings per
subsections (e)(1) and (e)(2) of this Section. If the laboratory that finds evidence
for any of those diseases listed in subsections (e)(1) and (e)(2) is an out-of-state
laboratory, the California clinical laboratory that receives a report of such
findings from the out-of-state laboratory shall notify the local health officer in
the same way as if the finding had been made by the California laboratory.
(e) Laboratory reports to the local health officer
shall include the information as specified in (c) of this Section and laboratories
shall submit the reports within the following timeframes:
(1) The diseases or agents specified shall be
reported within one hour after the health care provider or other person authorized
to receive the report has been notified. Laboratories shall make the initial reports
to the local health officer by telephone and follow the initial report within one
working day by a report to the state electronic reporting system or local electronic
reporting system that is linked to the state electronic reporting system. If
reporting to the state or local electronic system is not possible, reporting by
electronic facsimile transmission and electronic mail may temporarily substitute for
reporting to the state or local electronic reporting system. Laboratories shall also
report by other means (e.g., electronic facsimile) if requested by a local health
officer or the Department. Laboratory findings for these diseases are those that
satisfy the most recent communicable disease surveillance case definitions
established by the CDC (unless otherwise specified in this Section). The diseases or
agents reported pursuant to this requirement are:
* Anthrax, human (B. anthracis) (see section
2551 for additional reporting
instructions)
* Anthrax, animal (B. anthracis)
* Botulism (see section
2552 for additional reporting
instructions)
* Brucellosis, human (all Brucella spp.) (see
section 2553 for special reporting
instructions)
* Burkholderia pseudomallei and B.
mallei (detection or isolation from a clinical specimen)
* Coronavirus, novel strains
* Influenza, novel strains (human) (see (i) for additional
reporting requirements)
* Plague, human (see section
2596 for additional reporting
instructions)
* Plague, animal
* Smallpox (Variola) (see section
2614 for additional reporting
instructions)
* Tularemia, human (F. tularensis) (see
section 2626 for additional reporting
instructions)
* Viral Hemorrhagic Fever agents, human (VHF), e.g.,
Crimean-Congo, Ebola, Lassa, and Marburg viruses (see section
2638 for additional reporting
instructions)
* Viral Hemorrhagic Fever agents, animal (VHF), e.g.,
Crimean-Congo, Ebola, Lassa, and Marburg viruses
(2) The diseases or agents specified shall be
reported within one working day after the health care provider or other person
authorized to receive the report has been notified. Laboratories shall transmit
these reports to the state electronic reporting system or local electronic reporting
system that is linked to the state electronic reporting system, except for acute HIV
infection reporting which shall be reported by telephone (see (j) for specific acute
HIV infection reporting requirements). Acute HIV infection shall be reported both by
telephone and to the state electronic reporting system within one working day of
identification. If reporting to the state or local electronic reporting system is
not possible, reporting by electronic facsimile transmission or electronic mail may
temporarily substitute for reporting to the state or local electronic reporting
system. Laboratories shall also report by other means (e.g., electronic facsimile)
if requested by a health officer or the Department. Laboratory findings for these
diseases are those that satisfy the most recent communicable disease surveillance
case definitions established by the CDC (unless otherwise specified in this
Section). The diseases or agents reported pursuant to this requirement are:
* Acid fast bacillus (AFB) (see (g) for additional reporting
requirements)
* Anaplasmosis
* Babesiosis
* Bordetella pertussis acute infection, by
culture or molecular identification
* Borrelia burgdorferi infection
* Brucellosis, animal (Brucella spp. except
Brucella canis)
* Campylobacteriosis (Campylobacter spp.)
(detection or isolation a clinical specimen)
* Candida auris, colonization or infection
(see (r) for additional reporting requirements)
* Carbapenemase-producing organism, colonization or
infection
* Chancroid (Haemophilus ducreyi)
* Chikungunya virus infection
* Chlamydia trachomatis infections, including
lymphogranuloma venereum (LGV)
* Coccidioidomycosis
* Cryptosporidiosis
* Cyclosporiasis (Cyclospora
cayetanensis)
* Dengue virus infection
* Diphtheria
* Ehrlichiosis
* Encephalitis, arboviral
* Escherichia coli: shiga toxin producing
(STEC) including E. coli O157 (see (m) for additional reporting
requirements)
* Flavivirus infection of undetermined species
* Giardiasis (Giardia lamblia, intestinalis,
or duodenalis)
* Gonorrhea
* Haemophilus influenzae, all types
(detection of or isolation from a sterile site in a person less than 5 years of
age)
* Hantavirus Infections
* Hepatitis A, acute infection
* Hepatitis B, acute or chronic infection (specify
gender)
* Hepatitis C, acute or chronic infection
* Hepatitis D (Delta), acute or chronic infection
* Hepatitis E, acute infection (detection of hepatitis E virus
RNA from a clinical specimen or positive serology)
* Human Immunodeficiency Virus (HIV), acute infection (see (j)
for additional reporting requirements)
* Influenza
* Legionellosis (Legionella spp.) (antigen or
culture)
* Leprosy (Hansen Disease) (Mycobacterium
leprae)
* Leptospirosis (Leptospira spp.)
* Listeriosis (Listeria) (see (m) for
additional reporting requirements)
* Malaria (see (h) for additional reporting
requirements)
* Measles (Rubeola), acute infection
* Middle East Respiratory Syndrome Coronavirus
(MERS-CoV)
* Monkeypox or orthopox virus infection
* Mumps (mumps virus), acute infection
* Neisseria meningitidis (sterile site
isolate or eye specimen) (see (m) for additional reporting requirements)
* Poliovirus
* Psittacosis (Chlamydophila psittaci)
* Q Fever (Coxiella burnetii)
* Rabies, animal or human
* Relapsing Fever (Borrelia spp.)
(identification of Borrelia spp. spirochetes on peripheral blood
smear)
*Respiratory syncytial virus
* Rickettsia, any species, acute infection
(detection from a clinical specimen or positive serology)
* Rocky Mountain Spotted Fever (Rickettsia
rickettsii)
* Rubella, acute infection
* Salmonellosis (Salmonella spp.) (see
Section 2612(a) for additional
reporting requirements)
* Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
(see (p) and (q) for additional reporting requirements)
* Shiga toxin (detected in feces) (see (m) for additional
reporting requirements)
* Shigellosis (Shigella spp.) (see (m) for
additional reporting requirements)
* Syphilis
* Trichinosis (Trichinella)
* Tuberculosis, including Mycobacterium
tuberculosis complex (see (f) for additional reporting requirements)
* Latent Tuberculosis Infection identified by a positive
laboratory test (see (o) for additional reporting requirements)
* Tularemia, animal (F. tularensis)
* Typhoid
* Vibrio species infections
* West Nile virus infection
* Yellow Fever (yellow fever virus)
* Yersiniosis (Yersinia spp., non-pestis)
(isolation from a clinical specimen)
* Zika virus infection (see (m) for additional reporting
requirements)
(f) In
addition to notifying the local health officer pursuant to subsection (a), any
clinical laboratory or approved public health laboratory that isolates
Mycobacterium tuberculosis complex or identifies
Mycobacterium tuberculosis complex by molecular testing from a
patient specimen shall:
(1) Submit a culture as
soon as available from the primary isolate on which a diagnosis of tuberculosis was
established. Such a culture shall be submitted to the public health laboratory
designated in
Title 17 California Code of Regulations, Section
1075 for the local jurisdiction where
the patient resides. The following information shall be submitted with the culture:
the name, address, and the date of birth of the person from whom the specimen was
obtained, the patient identification number, the specimen accession number or other
unique specimen identifier, the date the specimen was obtained from the patient, and
the name, address, and telephone number of the health care provider for whom such
examination or test was performed. The public health laboratory shall retain the
culture received (one culture from each culture-positive patient) in a viable
condition for at least six months.
(A) If
Mycobacterium tuberculosis complex is identified by molecular
testing but no culture isolate is available, a specimen available to the laboratory
shall be submitted to the public health laboratory designated in
Title 17 California
Code of Regulations Section
1075 upon request from the local health
officer, public health laboratory, or the Department's Microbial Disease
Laboratory.
(2) Unless drug
susceptibility testing has been performed by the clinical laboratory on a strain
obtained from the same patient within the previous three months or the health care
provider who submitted the specimen for laboratory examination informs the
laboratory that such drug susceptibility testing has been performed by another
laboratory on a culture obtained from that patient within the previous three months,
the clinical laboratory shall:
(A) Perform or
refer for drug susceptibility testing on at least one isolate from each patient from
whom Mycobacterium tuberculosis complex was isolated; and
(B) Report the results of drug susceptibility
testing including molecular assays for drug resistance, if performed, to the local
health officer of the jurisdiction where the patient resides within one working day
from the time the health care provider or other authorized person who submitted the
specimen is notified; and
(C) If the
drug susceptibility testing determines the culture to be resistant to at least
isoniazid and rifampin, as soon as available, submit one culture or subculture from
each patient from whom multidrug-resistant
Mycobacterium
tuberculosis complex was isolated to the official public health laboratory
designated in
Title 17 California Code of Regulations Section
1075 for the local health jurisdiction
in which the patient resides. The local public health laboratory shall forward such
cultures to the Department's Microbial Diseases Laboratory. The following
information shall be submitted with the culture: the name, address, and the date of
birth of the person from whom the specimen was obtained, the patient identification
number, the specimen accession number or other unique specimen identifier, the date
the specimen was obtained from the patient, and the name, address, and telephone
number of the health care provider for whom such examination or test was
performed.
(g)
Whenever a clinical laboratory finds that a specimen from a patient with known or
suspected tuberculosis tests positive for acid fast bacillus (AFB) staining and the
patient has not had a culture which identifies that acid fast organism within the
past 30 days, the clinical laboratory shall culture and identify the acid fast
bacteria or refer a subculture to another laboratory for those purposes.
(h) In addition to notifying the local health
officer pursuant to subsection (a), any clinical laboratory that makes a finding of
malaria parasites in the blood film of a patient shall immediately submit one or
more such blood film slides for confirmation to the public health laboratory
designated in
Title 17 California Code of Regulations Section
1075 for the local health jurisdiction
where the patient resides. When requested, all blood films shall be returned to the
submitter.
(i) Whenever a laboratory
receives a specimen for the laboratory diagnosis of influenza, novel strains in a
human such laboratory shall communicate immediately by telephone with the
Department's Viral and Rickettsial Disease Laboratory for instruction.
(j) In addition to routine reporting requirements
set forth in section
2643.10, for acute HIV infection
reporting, laboratories shall report all cases within one working day to the local
health officer of the jurisdiction in which the patient resides by telephone. If the
patient residence is unknown, the laboratory shall notify the health officer of the
jurisdiction in which the health care provider is located. If evidence of acute HIV
infection is based on presence of HIV p24 antigen, laboratories shall not wait until
HIV-1 RNA is detected before reporting to the local health officer.
(k) All laboratory notifications herein required
are acquired in confidence and shall not be disclosed by the local health officer
except (1) as authorized by these regulations; (2) as required by state or federal
law; or (3) with the written consent of the individual to whom the information
pertains or the legal representative of that individual.
(l) The local health officer shall disclose any
information, including personal information, contained in a laboratory notification
to state, federal or local public health officials in order to determine the
existence of the disease, its likely cause and the measures necessary to stop its
spread.
(m) An isolate or a specimen as
listed in this subsection shall be submitted as soon as available to the public
health laboratory designated in Section
1075 for the local health jurisdiction
where the patient resides. The following information shall be submitted with the
isolate or specimen: the name, address, and the date of birth of the person from
whom the isolate or specimen was obtained, the patient identification number, the
isolate or specimen accession number or other unique identifier, the date the
isolate or specimen was obtained from the patient, the name, address, and telephone
number of the health care provider for whom such examination or test was performed,
and the name, address, telephone number and the laboratory director's name of the
laboratory submitting the isolate or specimen.
(1)
The specimens pursuant to the requirements in (m) are:
* Malaria positive blood film slides (see (h) for additional
reporting requirements)
* Neisseria meningitidis eye specimens
* Shiga toxin-positive fecal broths
* Zika virus immunoglobulin M (IgM)-positive sera
(2) The isolates pursuant to the
reporting requirements in (m) are:
* Drug resistant Neisseria gonorrhoeae
isolates (cephalosporin or azithromycin only)
* Listeria monocytogenes isolates
* Mycobacterium tuberculosis isolates (see
(f) for additional reporting requirements)
* Neisseria meningitidis isolates from
sterile sites
* Salmonella isolates (see section
2612 for additional reporting
requirements)
* Shiga toxin-producing Escherichia coli
(STEC) isolates, including O157 and non-O157 strains
* Shigella isolates
(3) If there is a laboratory test result
indicating infection with any one of the pathogens listed in (m)(2), then the
laboratory must attempt to obtain a bacterial culture isolate for submission to the
public health laboratory in accordance with (m)(2). This requirement includes
identification of Shiga toxin in a clinical specimen, but does not include latent
tuberculosis infection identified by a positive laboratory test. The laboratory
shall take steps necessary to obtain an isolate, including requesting that
additional specimens be collected and sending specimens to a laboratory able to
carry out bacterial culture as soon as possible.
(n) Upon written request and submission
instruction by the Department, a laboratory that receives a specimen that is
reactive for HIV-1/2 antigen or antibody, as defined within this subsection, shall
submit the specimen to either the local public health laboratory designated in
Section
1075 for the local health jurisdiction
where the patient resides, the State Public Health Laboratory, or their designee.
The specimen submission shall include the information identified in subdivision (m)
and the Clinical Laboratory Improvement Amendments number.
(1) For purposes of this subsection, the specimen
shall be defined as the HIV-1/2 antigen or antibody reactive sera or plasma
submitted as part of a diagnostic HIV test algorithm, as defined in section
2641.57
(o) Results of positive laboratory tests,
including positive interferon gamma release assays, should be reported including
quantitative components of results, if applicable.
(p) Upon written request and submission
instruction by the Department or a local health officer, a laboratory that tests any
specimen for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), shall
submit the specimen and any nucleic acid extract to either the local public health
laboratory designated in Section
1075 for the local health jurisdiction
where the patient resides, the State Public Health Laboratory, or their designee.
The specimen submission shall include the information identified in subdivision (b),
the Cycle Threshold (CT) or Relative Light Units (RLU) value, and the federal
Clinical Laboratory Improvement Amendments certificate number.
(q) A laboratory that performs genetic sequencing
of SARS-CoV-2 shall submit sequence data to the Department in an electronic format
specified by the Department. In addition, a laboratory that identifies a SARS-CoV-2
strain designated as a variant of public health importance by the Department shall
transmit the report in a format specified by the Department to the state electronic
reporting system or local electronic reporting system that is linked to the state
electronic reporting system. The sequence data submission and the strain report
shall include the information identified in subsection (c), and the federal Clinical
Laboratory Improvement Amendments certificate number if applicable.
(r) If a
Candida auris isolate(s)
is identified from a sterile site, and the laboratory has obtained a fungal culture
isolate, the isolate(s) must be submitted to a public health laboratory within 10
working days from the date of collection. The specimen submission shall include the
information identified in subdivision (m) and the Clinical Laboratory Improvement
Amendments number.
(1) Upon written request and
submission instruction by the Department or a local health officer, the laboratory
must attempt to obtain a fungal culture isolate from any specimen site for
submission as soon as available to the public health laboratory designated in
Section
1075 for the local health jurisdiction
where the patient resides.
Notes
Cal. Code Regs. Tit. 17, §
2505
1. New section
filed 3-26-62; effective thirtieth day thereafter (Register 62, No.6).
2.
Amendment of subsections (a) and (b) filed 6-25-72 as an emergency; effective upon
filing (Register 72, No. 27).
3. Certificate of Compliance filed 10-24-72
(Register 72, No. 44).
4. Amendment of subsection (d) filed 3-30-89;
operative 3-30-89 (Register 89, No. 14).
5. Amendment of section and NOTE
filed 5-1-95 as an emergency; operative 5-1-95 (Register 95, No. 18). A Certificate
of Compliance must be transmitted to OAL by 8-29-95 or emergency language will be
repealed by operation of law on the following day.
6. Amendment of
section and NOTE refiled 8-21-95 as an emergency; operative 8-21-95 (Register 95,
No. 34). A Certificate of Compliance must be transmitted to OAL by 12-19-95 or
emergency language will be repealed by operation of law on the following
day.
7. Certificate of Compliance as to 5-1-95 order, including amendment
of section, transmitted to OAL 12-19-95 and filed 2-2-96 (Register 96, No.
5).
8. Change without regulatory effect amending subsection (c) filed
7-15-97 pursuant to section
100, title 1, California Code of
Regulations (Register 97, No. 29).
9. Amendment of subsections (a)-(d),
repealer of subsection (e) and new subsections (e)-(e)(2) and amendment of NOTE
filed 11-5-2001 as an emergency; operative 11-5-2001 (Register 2001, No. 45). A
Certificate of Compliance must be transmitted to OAL by 3-5-2002 or emergency
language will be repealed by operation of law on the following day.
10.
Amendment of subsections (a)-(d), repealer of subsection (e), new subsections
(e)-(e)(2) and amendment of NOTE refiled 3-1-2002 as an emergency; operative
3-1-2002 (Register 2002, No. 9). A Certificate of Compliance must be transmitted to
OAL by 7-1-2002 or emergency language will be repealed by operation of law on the
following day.
11. Certificate of Compliance as to 3-1-2002 order,
including further amendment of subsection (e)(1), transmitted to OAL 6-26-2002 and
filed 7-16-2002 (Register 2002, No. 29).
12. Amendment of subsection
(e)(2) filed 6-30-2005; operative 6-30-2005. Submitted to OAL for printing only
pursuant to Health and Safety Code section
120130
(Register 2005, No. 32).
13. Amendment of subsection (e)(2) filed
10-26-2006; operative 10-26-2006. Submitted to OAL for printing only pursuant to
Health and Safety Code section
120130(a) and
(d) (Register 2006, No. 43).
14.
Amendment of subsections (e)(1)-(2), new subsections (i)-(j) and subsection
relettering filed 6-12-2007; operative 6-12-2007. Submitted to OAL for printing only
pursuant to Health and Safety Code section
120130
(Register 2007, No. 31).
15. Amendment of subsection (e)(2) filed
7-30-2007; operative 7-30-2007. Submitted to OAL for printing only pursuant to
Health and Safety Code section
120130
(Register 2007, No. 31).
16. Amendment of subsections (e)(1) and (e)(2)
and amendment of NOTE filed 9-22-2009; operative 9-22-2009. Submitted to OAL for
printing only pursuant to Health and Safety Code section
120130(a) and
(d) (Register 2009, No. 39).
17.
Amendment of subsections (e)(1)-(2), repealer of subsections (i)-(i)(4)(B),
subsection relettering and amendment of newly designated subsection (i) filed
6-30-2011; operative 6-30-2011. Submitted to OAL for printing only pursuant to
Health and Safety Code sections
120130(a)
and
120130(d)
(Register 2011, No. 26).
18. Amendment of subsection (e)(2) filed
9-27-2011; operative 10-27-2011. Submitted to OAL for printing only pursuant to
Health and Safety Code section
120130
(Register 2011, No. 39).
19. Amendment of subsection (e)(2), new
subsection (l) and amendment of NOTE filed 12-2-2013; operative 1-1-2014. Submitted
to OAL for printing only pursuant to Health and Safety Code section
120130
(Register 2013, No. 49).
20. Amendment of subsections (a), (a)(2) and
(e)(2), new subsection (j), subsection relettering, amendment of newly designated
subsection (m) and new subsections (m)(1)-(n) filed 5-24-2016; operative 5-24-2016.
Submitted to OAL for filing and printing only pursuant to Health and Safety Code
section
120130(a)-(b)
(Register 2016, No. 22).
21. Amendment filed 9-12-2019; operative
10-1-2019. Submitted to OAL for filing and printing only pursuant to Health and
Safety Code section
120130(a)-(b)
(Register 2019, No. 37).
22. Amendment of subsection (e)(1) filed
3-9-2020; operative 3-9-2020. Submitted to OAL for printing only pursuant to Health
and Safety Code section
120130
(Register 2020, No. 13).
23. Amendment of subsection (a)(2), new
subsection (a)(3) and amendment of subsections (b)-(c) and (e)(1)-(2) filed
7-28-2020; operative 7-28-2020. Submitted to OAL for printing only pursuant to
Health and Safety Code section
120130
(Register 2020, No. 31).
24. New subsection (p) and amendment of NOTE
filed 4-7-2021; operative 4-7-2021. Submitted to OAL for filing and printing only
pursuant to Health and Safety Code section
120130
(Register 2021, No. 15).
25. Amendment of subsection (e)(2) and new
subsection (q) filed 5-19-2021; operative 5-19-2021. Submitted to OAL for filing and
printing only pursuant to Health and Safety Code section
120130
(Register 2021, No. 21).
26. Amendment of subsection (e)(2) and new
subsections (r)-(r)(1) filed 8-24-2022; operative 8-24-2022. Submitted to OAL for
filing and printing only pursuant to Health and Safety Code section
120130
(Register 2022, No. 34).
27. Amendment of subsection (e)(2) filed
8-10-2023; operative 8-10-2023. Submitted to OAL for filing and printing only
pursuant to Health and Safety Code section
120130
(Register 2023, No. 32).
Note: Authority cited: Sections
100275,
120125,
120130,
120140,
125095,
131050,
131051,
131052,
131080
and
131200,
Health and Safety Code. Reference: Sections
100180,
120125,
120130,
120140,
120175,
120575,
121365,
125100
and
131080,
Health and Safety Code; Sections
1209,
1246.5
and
1288,
Business and Professions Code; Cal. Const., art. 1, Section
1; and Section
1040, Evidence
Code.
1. New section filed
3-26-62; effective thirtieth day thereafter (Register 62, No.6).
2.
Amendment of subsections (a) and (b) filed 6-25-72 as an emergency; effective upon
filing (Register 72, No. 27).
3. Certificate of Compliance filed 10-24-72
(Register 72, No. 44).
4. Amendment of subsection (d) filed 3-30-89;
operative 3-30-89 (Register 89, No. 14).
5. Amendment of section and Note
filed 5-1-95 as an emergency; operative 5-1-95 (Register 95, No. 18). A Certificate
of Compliance must be transmitted to OAL by 8-29-95 or emergency language will be
repealed by operation of law on the following day.
6. Amendment of
section and Note refiled 8-21-95 as an emergency; operative 8-21-95 (Register 95,
No. 34). A Certificate of Compliance must be transmitted to OAL by 12-19-95 or
emergency language will be repealed by operation of law on the following
day.
7. Certificate of Compliance as to 5-1-95 order, including amendment
of section, transmitted to OAL 12-19-95 and filed 2-2-96 (Register 96, No.
5).
8. Change without regulatory effect amending subsection (c) filed
7-15-97 pursuant to section 100, title 1, California Code of Regulations (Register
97, No. 29).
9. Amendment of subsections (a)-(d), repealer of subsection
(e) and new subsections (e)-(e)(2) and amendment of Note filed 11-5-2001 as an
emergency; operative 11-5-2001 (Register 2001, No. 45). A Certificate of Compliance
must be transmitted to OAL by 3-5-2002 or emergency language will be repealed by
operation of law on the following day.
10. Amendment of subsections
(a)-(d), repealer of subsection (e), new subsections (e)-(e)(2) and amendment of
Note refiled 3-1-2002 as an emergency; operative 3-1-2002 (Register 2002, No. 9). A
Certificate of Compliance must be transmitted to OAL by 7-1-2002 or emergency
language will be repealed by operation of law on the following day.
11.
Certificate of Compliance as to 3-1-2002 order, including further amendment of
subsection (e)(1), transmitted to OAL 6-26-2002 and filed 7-16-2002 (Register 2002,
No. 29).
12. Amendment of subsection (e)(2) filed 6-30-2005; operative
6-30-2005. Submitted to OAL for printing only pursuant to Health and Safety Code
section
120130
(Register 2005, No. 32).
13. Amendment of subsection (e)(2) filed
10-26-2006; operative 10-26-2006. Submitted to OAL for printing only pursuant to
Health and Safety Code section
120130(a) and
(d) (Register 2006, No. 43).
14.
Amendment of subsections (e)(1)-(2), new subsections (i)-(j) and subsection
relettering filed 6-12-2007; operative 6-12-2007. Submitted to OAL for printing only
pursuant to Health and Safety Code section
120130
(Register 2007, No. 31).
15. Amendment of subsection (e)(2) filed
7-30-2007; operative 7-30-2007. Submitted to OAL for printing only pursuant to
Health and Safety Code section
120130
(Register 2007, No. 31).
16. Amendment of subsections (e)(1) and (e)(2)
and amendment of Note filed 9-22-2009; operative 9-22-2009. Submitted to OAL for
printing only pursuant to Health and Safety Code section
120130(a) and
(d) (Register 2009, No. 39).
17.
Amendment of subsections (e)(1)-(2), repealer of subsections (i)-(i)(4)(B),
subsection relettering and amendment of newly designated subsection (i) filed
6-30-2011; operative 6-30-2011. Submitted to OAL for printing only pursuant to
Health and Safety Code sections
120130(a)
and
120130(d)
(Register 2011, No. 26).
18. Amendment of subsection (e)(2) filed
9-27-2011; operative 10-27-2011. Submitted to OAL for printing only pursuant to
Health and Safety Code section
120130
(Register 2011, No. 39).
19. Amendment of subsection (e)(2), new
subsection (l) and amendment of Note filed 12-2-2013; operative 1-1-2014. Submitted
to OAL for printing only pursuant to Health and Safety Code section
120130(Register
2013, No. 49).
20. Amendment of subsections (a), (a)(2) and (e)(2), new
subsection (j), subsection relettering, amendment of newly designated subsection (m)
and new subsections (m)(1)-(n) filed 5-24-2016; operative
5/24/2016. Submitted
to OAL for filing and printing only pursuant to Health and Safety Code section
120130(a)-(b)
(Register
2016, No. 22).
21. Amendment filed 9-12-2019; operative
10/1/2019. Submitted
to OAL for filing and printing only pursuant to Health and Safety Code section
120130(a)-(b)
(Register
2019, No. 37).
22. Amendment of subsection (e)(1) filed
3-9-2020; operative 3-9-2020. Submitted to OAL for printing only pursuant to Health
and Safety Code section
120130
(Register 2020, No. 13).
23. Amendment of subsection (a)(2), new
subsection (a)(3) and amendment of subsections (b)-(c) and (e)(1)-(2) filed
7-28-2020; operative 7/28/2020. Submitted to OAL for printing only pursuant
to Health and Safety Code section
120130
(Register
2020, No. 31).
24. New subsection (p) and amendment of Note
filed 4-7-2021; operative 4/7/2021. Submitted to OAL for filing and printing
only pursuant to Health and Safety Code section
120130
(Register
2021, No. 15).
25. Amendment of subsection (e)(2) and new
subsection (q) filed 5-19-2021; operative
5/19/2021. Submitted
to OAL for filing and printing only pursuant to Health and Safety Code section
120130
(Register
2021, No. 21).
26. Amendment of subsection (e)(2) and new
subsections (r)-(r)(1) filed 8-24-2022; operative 8-24-2022. Submitted to OAL for
filing and printing only pursuant to Health and Safety Code section
120130
(Register 2022, No. 34).
27. Amendment of subsection (e)(2) filed
8-10-2023; operative 8/10/2023. Submitted to OAL for filing and printing
only pursuant to Health and Safety Code section
120130
(Register
2023, No. 32).